<DOC>
	<DOCNO>NCT00000678</DOCNO>
	<brief_summary>To compare effectiveness zalcitabine ( dideoxycytidine ; ddC ) therapy zidovudine ( AZT ) treatment AIDS advance AIDS relate complex ( ARC ) patient already receive least 1 year AZT therapy define safety profile . ddC show antiviral effect , AZT know significantly decrease mortality reduce frequency opportunistic infection patient AIDS advance ARC . After 1 year AZT therapy , effectiveness tends diminish patient progress opportunistic infection high mortality rate . This may due emergence AZT resistant virus isolate patient long-term AZT therapy . These isolates still sensitive ddC . A study long-term effectiveness ddC patient AIDS advance ARC long-term AZT therapy warrant ( 1 ) ddC antiviral activity , ( 2 ) blood toxicity associate take ddC , ( 3 ) effectiveness ddC test tube study seem diminish decreased effectiveness AZT .</brief_summary>
	<brief_title>Dideoxycytidine ( Ro 24-2027 ) A Randomized , Open-Label , Comparative Study Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) Patients With AIDS Advanced ARC Who Have Received Long-Term AZT Therapy .</brief_title>
	<detailed_description>ddC show antiviral effect , AZT know significantly decrease mortality reduce frequency opportunistic infection patient AIDS advance ARC . After 1 year AZT therapy , effectiveness tends diminish patient progress opportunistic infection high mortality rate . This may due emergence AZT resistant virus isolate patient long-term AZT therapy . These isolates still sensitive ddC . A study long-term effectiveness ddC patient AIDS advance ARC long-term AZT therapy warrant ( 1 ) ddC antiviral activity , ( 2 ) blood toxicity associate take ddC , ( 3 ) effectiveness ddC test tube study seem diminish decreased effectiveness AZT . AMENDED : AZT administer orally every 4 5 hour . Patients second arm discontinue AZT take ddC two tablet every 8 hour . Duration study 1 year interim analysis do 6 month 75 percent enrollment end study . Original design : Patients AIDS advance ARC receive least 500 mg/day AZT least 48 week randomize 1 2 treatment arm . Patients first treatment arm continue current dose AZT .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Aerosolized pentamidine give , tolerated patient , Pneumocystis carinii pneumonia prophylaxis dose 300 mg every 4 week . Allowed maintenance treatment : Pyrimethamine ( = &lt; 75 mg/day ) . Sulfadiazine ( &lt; 4 gl/day ) . Amphotericin ( 1 mg/kg/day 5 day ) . Fluconazole ( 400 mg/day ) . Ketoconazole ( 400 mg/day ) . Acyclovir ( 12.4 mg/kg q8h IV zoster 4000 mg/day allow PO precaution nausea vomit possible dos &gt; 1000 mg/day ) . Ganciclovir ( 6 mg/kg/day ) . Medications tuberculosis Mycobacterium avium patient recover toxoplasmosis , cryptococcosis , candidiasis , herpes virus infection , cytomegalovirus infection , tuberculosis , Mycobacterium avium intracellulare . Erythropoietin megace need . Isoniazid patient peripheral neuropathy study entry take pyridoxine least 50 mg/day concomitantly . Phenytoin patient peripheral neuropathy study entry stable drug least 3 month . Patients must Pneumocystis carinii pneumonia ( PCP ) AIDS define opportunistic infection present zidovudine ( AZT ) therapy first initiate . Patients must : Advanced AIDS relate complex ( ARC ) . Antibody HIV federally license ELISA confirm Western blot analysis . Ability give conform consent . Exclusion Criteria Coexisting Condition : Patients exclude : Have zidovudine ( AZT ) therapy interrupt &gt; 30 consecutive day time AZT therapy AZT &gt; 90 day total . Have AZT therapy interrupt `` recurrent '' grade 4 toxicity , define &gt; one episode grade 4 toxicity dose interruption attenuation . Have visceral extensive Kaposi 's sarcoma require therapy malignancy require therapy . Have history peripheral neuropathy . Concurrent Medication : Excluded : Other experimental medication , include foscarnet , ribavirin , fluconazole ( prior IND approval ) . Other antiretroviral agent , biologic modifier corticosteroid . Drugs cause peripheral neuropathy include phenytoin ( condition specifically allow ) , hydralazine , metronidazole , nitrofurantoin , vincristine , cisplatinum , dapsone , disulfiram , diethyldithiocarbamate . Patients follow excluded : History peripheral neuropathy moderate severe peripheral neuropathy define combination sign symptoms peripheral neuropathy finding indicative peripheral neuropathy standardize neurologic exam . Active opportunistic infection . Participation another research treatment study . Prior Medication : Excluded : Dideoxycytidine ( ddC ) . Didanosine ( ddI ) . Active substance alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1992</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>